Skip to main content
. Author manuscript; available in PMC: 2015 Apr 2.
Published in final edited form as: Lancet Oncol. 2014 Feb 7;15(3):323–332. doi: 10.1016/S1470-2045(14)70012-9

Figure 1. Trial profile.

Figure 1

*Most common reason for screen failure included a negative cobas test for the BRAF mutation (1086 patients; 76%), brain metastases (110 patients; 8%), deterioration/ECOG status/death (46 patients; 3%). †Pulmonary embolism before treatment (one patient), not eligible per exclusion criteria (one patient), clinical deterioration (one patient), brain metastases (two patients), and two patients pending resolution on treatment status.